OncoTargets and Therapy · 2017 · 23 citations · 27 references
MedicineOncologyPathologyCancer ImmunologyNeoplasiaTumor ImmunologyCancer Survival AnalysisEsophageal CancerImmuno-oncology BiomarkersMalignant NeoplasmsSquamous Cell CarcinomaClinicopathologic FeaturesHazard Ratio ModelingNeutrophil-to-lymphocyte RatioPrognostic BiomarkersPrognostic IndicesSquamous Cell Carcinoma PathologyTumor Depth Of InvasionTumor Invasion Assessment
PURPOSE: Evidence from an increasing number of studies has demonstrated that the neutrophil-to-lymphocyte ratio (NLR) is a prognostic factor for various cancers. However, it is unclear whether NLR predicts prognosis in esophageal squamous cell carcinoma (ESCC). We conducted a meta-analysis to investigate the prognostic and clinicopathologic significance of NLR in patients with ESCC. PATIENTS AND METHODS: Selected studies were identified by searches in PubMed, Embase, and Web of Science databases and filtered using our prepared criteria. The hazard ratio (HR) and odds ratio were chosen as effect measures to assess the prognostic role of NLR and its clinicopathologic significance in ESCC. In total, nine studies containing 2,513 patients were enrolled. RESULTS: <0.001). Elevated NLR was also associated with unfavorable characteristics regarding depth of tumor invasion, tumor size, clinical stage, and differentiation degree. CONCLUSION: The results of our meta-analysis suggest that a high NLR value might represent a poor prognosis and worse clinicopathologic characteristics for patients with ESCC.
27
Ahmedin Jemal, Freddie Bray, Jacques Ferlay et al. · CA A Cancer Journal for Clinicians · 2011 · 55K citations · Full text
Global cancer statistics, 2012
Lindsey A. Torre, Freddie Bray, Rebecca L. Siegel et al. · CA A Cancer Journal for Clinicians · 2015 · 27.4K citations · Full text
Tumor-Infiltrating CD8<sup>+</sup>Lymphocytes Predict Clinical Outcome in Breast Cancer
Sahar Mahmoud, Emma C. Paish, Desmond G. Powe et al. · Journal of Clinical Oncology · 2011 · 1.4K citations · Full text
Life Sciences, Immunology, Oncology +17